News Category
Onco-Innovations has entered a letter of intent to secure an exclusive option on Ifowonco's oral small-molecule LAG-3 inhibitor program, potentially c...
Earth Science Tech's acquisition of Zoolzy is strategically important as it enhances its supply chain efficiency, potentially increasing profit margin...
SCHOTT Pharma's parent group's updated climate targets, validated by SBTi, now include absolute Scope 3 emissions reduction, shifting focus to value-c...
Helus Pharma reports progress in its Phase 3 program for HLP003 in major depressive disorder, with topline data expected in Q4 2026, and advances its ...
VERAXA Biotech has advanced its VXA-222 bispecific antibody-drug conjugate into the next development stage and expanded its patent portfolio, undersco...
Tonix Pharmaceuticals' receipt of FDA feedback for its Lyme disease prevention candidate TNX-4800 marks a significant step toward addressing the unmet...
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the p...
VERAXA Biotech names Christoph Erkel, Ph.D., as chief scientific officer to lead advancement of its BiTAC platform for solid tumor cancer therapies, s...
NanoViricides raises approximately $3.8 million through a registered direct offering, providing capital to advance its broad-spectrum antiviral drug c...
VERAXA Biotech AG appointed Christoph Erkel, Ph.D., as chief scientific officer to lead the development of its proprietary BiTAC platform for cancer t...
VERAXA Biotech AG announced that Germany's Paul-Ehrlich-Institute has provided Scientific Advice supporting the development strategy for its lead BiTA...
VERAXA Biotech announced regulatory feedback from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE cancer therapy, advancing the program toward clin...
Siegfried appoints Eduardo Montanha as Chief Operating Officer, effective September 1, 2026, to lead integrated end-to-end solutions across the pharma...
NextPlat Corp announced a $1.5 million cash acquisition of an independent pharmacy in rural Florida, expected to close in Q4 2026, expanding its Pharm...
Onco-Innovations announced the completion of its analytical reference standard program for ONC010's active ingredient, strengthening its CMC framework...
VERAXA Biotech (NASDAQ: VRXA) has initiated cell line development for its lead BiTAC T-cell engager program, selecting ATUM to support manufacturing d...
The sustained release polymers market is projected to grow at a CAGR of 7.4% from 2026 to 2036, driven by rising chronic disease prevalence, increasin...
VERAXA Biotech AG reported progress in its proprietary BiTAC platform, with four T-cell engager programs targeting solid tumors, and is pursuing partn...
VERAXA Biotech has started cell line development for its BiTAC T-cell engager through a collaboration with ATUM, aiming to improve tumor selectivity a...
Recent strategic partnerships and licensing agreements in antibody-drug conjugates and T-cell engagers highlight the potential for early-stage biotech...
Ace Therapeutics announces a full-spectrum pain research platform with diverse in vivo pain models and end-to-end preclinical services to accelerate a...
Medios AG closes its Aschaffenburg facility and consolidates patient-specific manufacturing to improve efficiency amid margin pressure from price regu...
Helus Pharma announced fiscal 2026 financial results and clinical pipeline updates, emphasizing the Phase 3 APPROACH trial for HLP003 in major depress...
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
Knight Therapeutics announced the full repayment of its $60 million revolving credit facility used to fund the Paladin acquisition, highlighting stron...
Voyageur Pharmaceuticals is evaluating three potential locations in the U.S. for its integrated iodine and barium contrast media manufacturing facilit...
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emphasizing...
Voyageur Pharmaceuticals has applied for a five-year exploration permit at its Frances Creek barite project in British Columbia, aiming to conduct bul...
Voyageur Pharmaceuticals closed a $5 million private placement to fund FDA licensing for its barium contrast products, regulatory approvals for the Fr...
Kairos Pharma announced plans to acquire worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor, and highlighted clinical milestones ...
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by repairing nerve damage, while its commercial product u...
Quantum BioPharma Ltd. is advancing a clinical-stage multiple sclerosis program targeting demyelination, with a completed Phase 1 safety study and IND...
Redwood AI Corp. announced DTC eligibility for its common shares, simplifying U.S. trading and liquidity, and engaged InvestorBrandNetwork for a $114,...
Carmed Pharmaceuticals leverages editorial coverage in CityBiz to detail its founder's journey, formulation philosophy, and multi-channel U.S. expansi...
Sino Biological's new XPressMAX™ kit enables ultra-fast, high-throughput protein synthesis in 3 hours, bridging the gap between AI-driven screening an...
NanoViricides reported progress on its broad-spectrum antiviral candidate NV-387, including regulatory approval for Phase II MPox trials in the Democr...
NanoViricides announced a $2 million registered direct offering with an institutional investor, providing capital to support its clinical-stage broad-...
Lanterna Pharma raised $4.4 million through a registered direct offering and concurrent private placement, providing capital to advance its AI-powered...
Tonix Pharmaceuticals announces its participation in two May investor conferences, highlighting its commercial-stage CNS and immunology pipeline.
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model, providing a real-time web-based molecular intellige...
LIXTE Biotechnology Holdings is advancing its first-in-class PP2A inhibitor LB-100, designed to improve effectiveness of chemotherapy and immunotherap...
A recent article showcases Soligenix's use of synthetic hypericin across multiple dermatologic indications, emphasizing the efficiency and risk manage...
PolyPeptide Group AG's shareholders overwhelmingly approved all proposals, including board re-elections and financial reports, at the fifth annual Gen...
LIXTE Biotechnology Holdings filed its 2025 Form 10-K, detailing a transformational year with clinical advances for LB-100, the acquisition of Liora T...
LIXTE Biotechnology holds the world's only clinical-stage PP2A inhibitor, LB-100, which enhances cancer cell sensitivity to therapies and disrupts tum...
Lonza has nominated Stephen Fry, former Eli Lilly executive, to its board, aiming to strengthen governance and performance culture ahead of the 2026 A...
Voyageur Pharmaceuticals is progressing its vertically integrated barium and iodine contrast media projects with bankable feasibility studies, FDA sub...
Soligenix received a positive opinion from the EMA's Committee for Orphan Medicinal Products for dusquetide in Behçet's disease, unlocking development...
